Recommendations for Shire as of October 30



Analysts’ ratings

Shire (SHPG) stock has risen ~23% over the last 12 months and ~12.8% year-to-date. Analysts’ estimates show that the stock has a potential to return ~15.8% over the next 12 months. Analysts’ recommendations show a 12-month target price of $202.45 compared to the last price of $174.90 on October 27. 

The above chart shows analysts’ recommendations for Shire stock over the last 12 months.

Article continues below advertisement

Analysts’ recommendations

There are 11 analysts tracking Shire stock as of October 30. Four of them are recommending a “strong buy,” five are recommending a “buy,” and two are recommending a “hold.” None of them have recommended a “sell.” The changes in analysts’ estimates and recommendations are based on changing trends in the stock and the company’s performance.

The consensus rating for Shire is 1.82, which represents a “buy” for momentum investors and long-term growth investors.

Shire’s valuation

As of October 30, Shire was trading at a forward PE multiple of 11.2x compared to the industry average of 17.5x. It was trading at a forward EV[1. enterprise value]-to-EBITDA multiple of 10.5x compared to the industry average of 13.3x. Its forward EV-to-revenue multiple was 4.5x compared to the industry average of 4.6x.

The VanEck Vectors Biotech ETF (BBH) holds 5.4% of its total investments in Shire (SHPG), 4.9% in Biogen (BIIB), 5.2% in Allergan (AGN), and 8.4% in Amgen (AMGN).


More From Market Realist